675 related articles for article (PubMed ID: 18950515)
1. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
3. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
4. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Diaz LK; Cryns VL; Symmans WF; Sneige N
Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
[TBL] [Abstract][Full Text] [Related]
8. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
Ariazi EA; Clark GM; Mertz JE
Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
[TBL] [Abstract][Full Text] [Related]
12. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.
Nogi H; Kobayashi T; Suzuki M; Tabei I; Kawase K; Toriumi Y; Fukushima H; Uchida K
Oncol Rep; 2009 Feb; 21(2):413-7. PubMed ID: 19148516
[TBL] [Abstract][Full Text] [Related]
13. Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.
Wen YH; Ho A; Patil S; Akram M; Catalano J; Eaton A; Norton L; Benezra R; Brogi E
Breast Cancer Res Treat; 2012 Aug; 135(1):93-102. PubMed ID: 22538771
[TBL] [Abstract][Full Text] [Related]
14. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
16. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
[TBL] [Abstract][Full Text] [Related]
17. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
18. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.
Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J
Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
20. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]